{
    "organizations": [],
    "uuid": "9cebc9ac6be93f430321aa9574e1485425eb214d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-lenti-d-for-the-treatment-of-cerebral-adrenoleukodystrophy-idUSASC0A3D5",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - bluebird bio Inc:\n* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-Dâ„¢ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY\n* BLUEBIRD BIO INC - BREAKTHROUGH THERAPY DESIGNATION IS SUPPORTED BY PRELIMINARY DATA FROM ONGOING PHASE 2/3 STARBEAM STUDY (ALD-102) Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T21:02:00.000+03:00",
    "crawled": "2018-05-24T20:36:54.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "bluebird",
        "bio",
        "inc",
        "fda",
        "grant",
        "breakthrough",
        "therapy",
        "designation",
        "treatment",
        "cerebral",
        "adrenoleukodystrophy",
        "bluebird",
        "bio",
        "inc",
        "breakthrough",
        "therapy",
        "designation",
        "supported",
        "preliminary",
        "data",
        "ongoing",
        "phase",
        "starbeam",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}